Blog

At this conference, OraSure Technologies, Inc. had speakers on behalf of its subsidiary companies Novosanis, Diversigen, and DNA Genotek. If you were unable to attend any of these four presentations, we have captured the highlights for you here.

It's been an exciting year - using various media, including webinars, conferences, posters and scientific publications, we have had the opportunity to share our latest work in urine sampling for infectious disease and oncology research and applications. As we wrap up the year, here's our 2022 urine...

Highlights of our experience at AACC 2022 Our teams from DNA Genotek, Novosanis , and OraSure came together at AACC 2022, where we had the opportunity to meet industry experts, leading healthcare professionals, as well as our customers. We also hosted a scientific workshop at the conference. Our...

Given the disproportionate impact of STIs and HIV on the same populations, more convenient STI testing methods are needed to reach groups at risk. PrEP provides the opportunity to reach people at highest HIV and STI risk, expanding HIV prevention and optimizing STI services. Urine has shown to be a more accepted and effective sample type to detect several STIs.

Article by: Sanna Abbasi, PhD, and Arya Mehta Defining precision medicine and its aim Urine as a liquid biopsy for oncology applications - Novosanis OMNIgene™•SKIN: a validated skin microbiome collection system - DNA Genotek OMNIgene™•GUT Dx: a new benchmark for gut microbiome collection - DNA...

In April 2022, our team was present with a booth at Eurogin in Düsseldorf , a leading conference focusing on Human Papillomavirus (HPV) . It was a great place to share our latest work and stay up to date in the field of cervical cancer and other HPV-related diseases . We have three main takeaways...

Ovarian cancer (OC) is the seventh most common malignancy among women worldwide. More than 70% of women present the disease at an advanced stage, making the cancer type the most lethal of all gynecological malignancies.

Due to the recent surge in COVID-19 cases, including variants such as Omicron and its associated supply chain issues, the FDA announced an update to their device shortage list to include all blood specimen collection tubes . Their recommendations are to employ conservation strategies, including...

Urine as a sample type is well-accepted, and often preferred by women. As urine can detect HPV, the most common cause of cervical cancer, the sample type has potential to reach a wider population for cervical cancer screening.

At-home urine sampling: A way to continue healthcare practices to prevent the next global health crisis COVID-19 disrupted important cancer screening The COVID-19 pandemic has brought several challenges to healthcare . Lockdowns and fear of getting the infection caused many patients to cancel or...

Given the challenges with some traditional screening and detection methods, researchers are continuously exploring alternative methods to detect cancer types.